.Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G04B_Urologicals.G04BD08_Solifenacin.Solifenacin .Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G04B_Urologicals.G04BD08_Solifenacin.Solifenacin| name: | Solifenacin |
| ATC code: | G04BD08 | route: | oral |
| n-compartments | 2 |
Solifenacin is an antimuscarinic medication used primarily for the treatment of overactive bladder with symptoms of urinary frequency, urgency, and incontinence. It is an approved prescription drug and widely used in clinical practice to manage symptoms of urinary incontinence.
Reported pharmacokinetic parameters in healthy adult subjects after single oral administration.
Tannenbaum, S, et al., & Newgreen, D (2020). Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity. Pharmacology research & perspectives 8(6) e00684–None. DOI:10.1002/prp2.684 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33231929
Taekema-Roelvink, ME, et al., & Smulders, RA (2005). Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study. Clinical therapeutics 27(9) 1403–1410. DOI:10.1016/j.clinthera.2005.09.002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16291413
Abrams, P, & Andersson, KE (2007). Muscarinic receptor antagonists for overactive bladder. BJU international 100(5) 987–1006. DOI:10.1111/j.1464-410X.2007.07205.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/17922784